Rebus Holdings, Inc. (RBSH) Research

Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.

Market snapshot

Symbol
RBSH
Price
$0.00
Day change
0.00%
Market cap
$3.2K
P/E ratio
-0.00x
52-week range
0.0001-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Anthera Pharmaceuticals, Inc. (ANTH)
  • Comera Life Sciences Holdings, Inc. (CMRA)
  • FluoroPharma Medical, Inc. (FPMI)
  • GlobeImmune, Inc. (GBIM)
  • New Leaf Ventures Inc (NLVVF)
  • Neurobiological Technologies, Inc. (NTII)
  • PhaseRx, Inc. (PZRXQ)
  • Sienna Biopharmaceuticals, Inc. (SNNAQ)

Open Rebus Holdings, Inc. (RBSH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.